Michael Gold to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Michael Gold has written about Randomized Controlled Trials as Topic.
Connection Strength
1.463
-
Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007 Mar; 68(3):430-8.
Score: 0.205
-
Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI). Am Heart J. 2006 Aug; 152(2):231-6.
Score: 0.197
-
The Rhythm ID Going Head to Head Trial (RIGHT): design of a randomized trial comparing competitive rhythm discrimination algorithms in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 2006 Jul; 17(7):749-53.
Score: 0.196
-
Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. Am Heart J. 2019 11; 217:13-22.
Score: 0.118
-
Prophylactic pulmonary vein isolation during cavotricuspid isthmus ablation for atrial flutter: A meta-analysis. Pacing Clin Electrophysiol. 2019 05; 42(5):493-498.
Score: 0.118
-
The rationale and design of the SMART CRT trial. Pacing Clin Electrophysiol. 2018 09; 41(9):1212-1216.
Score: 0.113
-
Modeling Alzheimer's disease progression using the disease system analysis approach. Alzheimers Dement. 2012 Jan; 8(1):39-50.
Score: 0.069
-
Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Curr Heart Fail Rep. 2009 Mar; 6(1):44-8.
Score: 0.059
-
Pacing Evaluation-Atrial SUpport Study in Cardiac Resynchronization Therapy (PEGASUS CRT): design and rationale. Am Heart J. 2007 Jan; 153(1):7-13.
Score: 0.051
-
ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J. 2006 Sep; 152(3):442-7.
Score: 0.049
-
Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J. 2006 Feb; 151(2):288-94.
Score: 0.048
-
Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation. 2023 Mar 07; 147(10):812-823.
Score: 0.039
-
Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1981-5.
Score: 0.033
-
Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights From ASSERT. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008655.
Score: 0.032
-
Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review. Vaccine. 2018 09 25; 36(40):6007-6016.
Score: 0.028
-
Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
Score: 0.027
-
Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
Score: 0.026
-
HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014 Jul 01; 130(1):94-125.
Score: 0.021
-
An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
Score: 0.020
-
Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain. 2009 Jul-Aug; 25(6):469-76.
Score: 0.015